PEG

SNX7886 is a potent PROTAC designed to selectively degrade CDK8 and CDK19 proteins, effectively targeting these kinases in cellular systems.

DB1113 is a bifunctional compound designed for targeted protein degradation of various kinases. It effectively mediates the degradation of multiple kinase targets, facilitating the study of processes related to dysregulated kinase activity.

SJ1008030 TFA is a PROTAC specifically designed to target and degrade JAK2. This compound demonstrates selective inhibition of cell growth in MHH–CALL-4 cells, making it useful for studying mechanisms related to leukemia.

LC-MB12 is an orally active PROTAC designed for the degradation of FGFR2. This compound integrates a FGFR2 inhibitor, a PROTAC linker, and a cereblon-binding moiety, effectively disrupting FGFR2 signaling in gastric cancer cells. Its structural components facilitate targeted protein degradation, highlighting its potential in research focused on tumor biology.

PROTAC GPX4 degrader-1 (DC-2) is a PROTAC designed for the targeted degradation of GPX4. This compound employs a structure that facilitates the selective elimination of GPX4, highlighting its utility in studies related to oxidative stress and cellular regulation.

C004019 is a small-molecule PROTAC that effectively recruits tau proteins and the E3 ligase VHL, promoting selective ubiquitination and degradation of tau. Its structural design facilitates targeted protein turnover, making it valuable for investigations related to tau pathology.

PROTAC ER Degrader-4 is a von Hippel-Lindau-derived PROTAC designed to target the estrogen receptor (ER) for degradation. Its structural components facilitate efficient binding to ER, promoting the degradation of the receptor in relevant cell models.

BETd-246 is a second-generation PROTAC that targets BET bromodomains by linking ligands for Cereblon and BET. Its structural design enhances selectivity and potency, making it effective in promoting degradation of BET proteins.

ARV-393 is an orally bioavailable PROTAC designed to promote the degradation of BCL6 through the ubiquitin-proteasome pathway. Its structure incorporates ligand conjugates that specifically target BCL6 and the E3 ligase cereblon. This compound shows significant activity in various cell lines associated with diffuse large B-cell lymphoma and Burkitt lymphoma, demonstrating effective tumor suppression in xenograft models.